David Shaw

A technology showcase

As quantum hardware advances, the distinction between Noisy Intermediate-Scale Quantum (NISQ) systems and fault-tolerant quantum computing is becoming a central focus in the race to develop scalable quantum technologies. This panel will bring together the leaders driving these developments to  explore the challenges and breakthroughs in qubit development and the journey from NISQ systems to fully fault-tolerant quantum computers. 

Key topics to be addressed by these industry leaders include: 

• What are the key differences between NISQ-era quantum systems and fault-tolerant quantum computing? 
• How are researchers and industry working to increase qubit counts while improving qubit quality and coherence times? 
• What are the practical challenges in scaling quantum hardware, and how do error correction and fault tolerance play a role in this progression? 
• What are the real-world applications for NISQ systems, and how far are we from transitioning to fault-tolerant quantum machines capable of solving larger, more complex problems? 
• How are industry and academia addressing the current limitations in qubit development, and what advancements can we expect in the near future for more robust quantum hardware? 

This session will provide insights into the evolving landscape of quantum hardware, the ongoing efforts to scale qubits, and the future potential of fault-tolerant quantum computing. 

Quantum computing has the potential to revolutionize the pharmaceutical and life sciences industries by solving complex problems that are currently beyond the reach of classical computers. This panel will explore how quantum technology is being applied to accelerate drug discovery, optimize molecular modeling, and enhance personalized medicine, among other innovations. 

Key topics include: 

• How is quantum computing being utilized in drug discovery, and what breakthroughs can it enable in the search for new therapies and treatments? 
• In what ways can quantum computing enhance molecular modeling and simulations, allowing for more accurate predictions of drug interactions and protein folding? 
• What role could quantum algorithms play in advancing genomics and personalized medicine, enabling more precise and efficient healthcare solutions? 
• What are the current limitations of quantum computing in pharma and life sciences, and how can companies and researchers prepare for the future integration of this technology? 
• How are pharmaceutical companies, research institutions, and quantum technology providers collaborating to advance quantum applications in life sciences? 

This panel will provide a deep dive into the opportunities and challenges that quantum computing presents for the pharma and life sciences sectors, highlighting its potential to drive the next wave of innovation in healthcare and medicine. 

As the quantum race intensifies, particularly with the growing threat from China, it’s crucial for National Labs and federal institutions to collaborate effectively to maintain U.S. leadership in quantum technologies. This panel will examine the strategic funding, legislation, and collaborative efforts necessary to advance quantum research and development. 

Key discussion points include: 

• How are National Labs and federal institutions coordinating efforts to ensure the U.S. stays at the forefront of the global quantum race? 
• In what ways are public-private partnerships facilitating funding and driving successful quantum initiatives? 
• How are education programs being aligned with industry needs to cultivate a skilled workforce capable of supporting quantum advancements? 
• What alliances are emerging among governmental, academic, and industry players to promote and advance quantum research and applications? 
• What are the opportunities and challenges in accelerating bilateral and multilateral collaborations to bolster U.S. quantum capabilities? 
• How does the current legislative landscape impact funding and strategic priorities for quantum technology development? 

This closing keynote panel will provide valuable insights into the collaborative frameworks and strategic initiatives necessary to secure U.S. leadership in quantum technologies amidst increasing global competition. 

Exploring the drivers for continuing sovereign engagement in quantum. How do governments see the opportunity and what levers they are seeking to pull. What is the size of the prize?